Charles Schwab
CMPI

Charles Schwab’s Checkmate Pharmaceuticals, Inc. Common Stock CMPI Stock Holding History

Charles Schwab’s Portfolio CMPI Stock Details CMPI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-19,146
Closed -$233K – 3592
2021
Q1 		$233K Buy
19,146
+8,767
+84% +$125K ﹤0.01% 3299
2020
Q4 		$152K Hold
10,379
– – ﹤0.01% 3288
2020
Q3 		$120K Buy
+10,379
New +$133K ﹤0.01% 3239

Other funds holding CMPI

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
CCP
Clough Capital Partners Boston, Massachusetts $1.04B AUM 49.7% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Charles Schwab's CMPI Position: Q2 2021 in Review

Charles Schwab sold out of Checkmate Pharmaceuticals, Inc. Common Stock (CMPI) in Q2 2021, closing a stake of 19,146 shares — an estimated $233K sold.

Charles Schwab first reported a position in CMPI in Q3 2020 and held it in 3 quarters. The position peaked at $233K in Q1 2021. 34 funds tracked by Wall St. Rank hold CMPI as of Q2 2021.

  • Charles Schwab reported no remaining Checkmate Pharmaceuticals, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Charles Schwab sold 19,146 Checkmate Pharmaceuticals, Inc. Common Stock shares in Q2 2021, an estimated $233K.
  • Charles Schwab first reported a position in Checkmate Pharmaceuticals, Inc. Common Stock in Q3 2020 and held it in 3 quarters.
  • Charles Schwab's Checkmate Pharmaceuticals, Inc. Common Stock position peaked at $233K in Q1 2021.
  • 34 funds tracked by Wall St. Rank held Checkmate Pharmaceuticals, Inc. Common Stock as of Q2 2021.

Based on Charles Schwab's 13F filing for Q2 2021, filed 16 Aug 2021.